lenalidomide has been researched along with enasidenib in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (enasidenib) | Trials (enasidenib) | Recent Studies (post-2010) (enasidenib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 96 | 11 | 94 |
| Protein | Taxonomy | lenalidomide (IC50) | enasidenib (IC50) |
|---|---|---|---|
| Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens (human) | 4.95 | |
| Isocitrate dehydrogenase [NADP], mitochondrial | Homo sapiens (human) | 0.3335 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Estey, EH; Percival, MM | 1 |
1 review(s) available for lenalidomide and enasidenib
| Article | Year |
|---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |